Bicara Therapeutics Inc. ... (BCAX)
NASDAQ: BCAX
· Real-Time Price · USD
12.06
0.06 (0.50%)
At close: Sep 04, 2025, 3:59 PM
12.06
0.00%
After-hours: Sep 04, 2025, 04:04 PM EDT
0.50% (1D)
| Bid | 10.64 |
| Market Cap | 658.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.67M |
| EPS (ttm) | -4.66 |
| PE Ratio (ttm) | -2.59 |
| Forward PE | -4.42 |
| Analyst | Buy |
| Ask | 12.3 |
| Volume | 199,160 |
| Avg. Volume (20D) | 474,351 |
| Open | 11.98 |
| Previous Close | 12.00 |
| Day's Range | 11.56 - 12.13 |
| 52-Week Range | 7.80 - 28.09 |
| Beta | -1.41 |
About BCAX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BCAX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BCAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-40.8%
Bicara Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
3 months ago
+7.33%
Bicara Therapeutics shares are trading lower after the company announced a publication of phase 1/1b trial data for ficerafusp alfa showing mixed results, with median survival still unreached and limited clarity on long-term efficacy.
2 months ago · seekingalpha.com
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From MerusMRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative...